Methotrexate in steroid-dependent asthma: long-term results
| Autor: | P. Silkoff, Robert J. Shiner, Ido Katz, T. Shulimzon, S Benzaray |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Adult
Male Budesonide Toxic hepatitis medicine.medical_specialty Time Factors Immunology Gastroenterology Liver Function Tests Pregnenediones Prednisone Internal medicine Pulmonary fibrosis medicine Humans Immunology and Allergy Prospective Studies Aged Asthma business.industry Beclomethasone Middle Aged medicine.disease Bronchodilator Agents Surgery Methotrexate Treatment Outcome Liver Abnormal Liver Function Test Drug Therapy Combination Female Steroid dependent asthma medicine.symptom business Follow-Up Studies medicine.drug |
| Zdroj: | Allergy. 49:565-568 |
| ISSN: | 1398-9995 0105-4538 |
| DOI: | 10.1111/j.1398-9995.1994.tb01130.x |
| Popis: | Treatment of 21 steroid-dependent asthmatic patients with methotrexate (MTX) 15 mg/week was prospectively evaluated for a mean of 14.7 (SD 3.7) months. Before MTX, therapy consisted of a mean prednisone dose of 16.6 (SD 9.2) mg, in addition to inhaled beclomethasone/budesonide (mean daily dose 1157 (SD 330) micrograms) and bronchodilators. Thirteen patients were weaned from all regular systemic steroid therapy, a 50% or more reduction was achieved in four patients, and a less than 50% reduction in four patients. Abnormal liver function tests were noted in six of the 21 patients; this resolved despite continuation of MTX in five. In one patient, MTX was stopped because of symptoms as well as a fivefold rise in serum transaminases, and a speedy resolution was noted. Gastrointestinal side-effects were reported in six patients but were resolved in five with intramuscular MTX. There were no hematologic or pulmonary complications. We conclude that MTX appears to be both safe and efficacious as a steroid-sparing agent in most steroid-dependent asthmatic patients when taken over a long period. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text